Comment
The authors suggest that tenofovir + 3TC + nevirapine should be studied further before being widely deployed in the community. Such study is unlikely to happen, though, given that the regimen appears to be inferior. As noted in an accompanying editorial, nevirapine-based regimens will continue to be important in countries with substantial numbers of reproductive-age women who need antiretroviral therapy. In the meantime, clinicians should be cautious about recommending regimens that guidelines deem to be "similar" when in fact they are not.
AIDS Clinical Care © 2012 Massachusetts Medical Society
